Albireo Pharma (FRA:BDQM) Days Payable : 895.00 (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Days Payable?

Albireo Pharma's average Accounts Payable for the three months ended in Sep. 2022 was €6.06 Mil. Albireo Pharma's Cost of Goods Sold for the three months ended in Sep. 2022 was €0.62 Mil. Hence, Albireo Pharma's Days Payable for the three months ended in Sep. 2022 was 895.00.

The historical rank and industry rank for Albireo Pharma's Days Payable or its related term are showing as below:

FRA:BDQM' s Days Payable Range Over the Past 10 Years
Min: 930.08 Med: 1587.99 Max: 1587.99
Current: 930.08

During the past 13 years, Albireo Pharma's highest Days Payable was 1587.99. The lowest was 930.08. And the median was 1587.99.

FRA:BDQM's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 152.29 vs FRA:BDQM: 930.08

Albireo Pharma's Days Payable declined from Sep. 2021 (1,355.41) to Sep. 2022 (895.00). It may suggest that Albireo Pharma accelerated paying its suppliers.

Albireo Pharma Days Payable Historical Data

The historical data trend for Albireo Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Days Payable Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Payable

Get a 7-Day Free Trial

1,537.56

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Payable	Get a 7-Day Free Trial															1,355.41	663.26	2,485.70	676.67	895.00

Competitive Comparison of Albireo Pharma's Days Payable

For the Biotechnology subindustry, Albireo Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albireo Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Days Payable falls into.

Albireo Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Albireo Pharma's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

	Days Payable (A: Dec. 2021 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2020 )	+	Accounts Payable (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (4.343	+	5.767)	/	2 )	/	1.2	*	365
=	5.055					/	1.2	*	365
=	1,537.56

Albireo Pharma's Days Payable for the quarter that ended in Sep. 2022 is calculated as:

	Days Payable (Q: Sep. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2022 )	+	Accounts Payable (Q: Sep. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
=	( (5.103	+	7.02)	/	2 )	/	0.618	*	365 / 4
=	6.0615					/	0.618	*	365 / 4
=	895.00

Albireo Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines